Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) posted its quarterly earnings data on Wednesday, May, 10th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.23) by $0.07. The company had revenue of $0.10 million for the quarter, compared to analyst estimates of $0.10 million. View Synergy Pharmaceuticals' Earnings History.

9 equities research analysts have issued twelve-month target prices for Synergy Pharmaceuticals' shares. Their predictions range from $3.70 to $18.00. On average, they expect Synergy Pharmaceuticals' stock price to reach $11.13 in the next twelve months. View Analyst Ratings for Synergy Pharmaceuticals.

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (7/18/2017)
• 2. HC Wainwright analysts commented, "We remain confident that Synergy should secure this key extension to the Trulance™ label in early 2018, and thereby should be able to compete on an equal footing across the board with its closest comparator, Linzess® (linaclotide), from Allergan plc (AGN; not rated) and Ironwood Pharmaceuticals (IRWD; not rated). We continue to anticipate that Trulance™ should be able to achieve a market-leading position in treatment of both chronic idiopathic constipation (CIC) and IBS-C in the coming years." (6/12/2017)
• 3. Cantor Fitzgerald analysts commented, "GC-C expertise should create new drugs and opportunities. SGYP’s pipeline leverages the company’s knowledge in modulating the effects of guanylate cyclase type C (GC-C) receptors to treat GI disorders. Lead drug candidates plecanatide and dolcanatide are designed to mimic the effects of the endogenous peptide hormone uroguanylin to restore normal GI function. We believe the strategy could lower the risk profile of the drug development programs. Trulance could be just what the Dr. ordered. Gastroenterologists we speak with acknowledge the relative effectiveness of CIC drugs but believe there is room for improvement particularly as it relates to tolerability. Amitiza and Linzess side effects may limit their usefulness and it would appear that Trulance produces a narrower range of them. With an sNDA recently filed for the IBS-C indication, SGYP could be in a position to create a new commercial opportunity in early 2018." (6/1/2017)
• 4. BTIG Research analysts commented, "With the US launch of Trulance (3 mg plecanatide, for the treatment of chronic constipation) now officially underway, investor focus now turns to the ramp for Trulance in the US market. We continue to believe management is up to the task of successfully launching Trulance via its hybrid sales model (utilizing an experienced contract sales force of ~150 - 200 reps), which is expected to target ~27,000 high-prescribing physicians. While we believe formulary access for Trulance could take up to 6 months, we think most insurance plans will put Trulance on a Tier 3 co-pay, with the Co. offering its 'savings to go' program as an offset. Our channel checks with several local pharmacies in NYC this morning suggest that this program will enable patients to get access to Trulance at a much lower cost (no more than $25 per Rx). Management also recently highlighted at an investor conference earlier today that a nationwide sampling program is underway. In sum, we expect the launch of Trulance to lead to more patients switching from OTC laxatives to Rx treatments, with Trulance leading to an expansion of the overall Rx market." (3/21/2017)
• 5. Guggenheim analysts commented, "After the close, SGYP reported 4Q16 financial results and provided a business update. There was not much new in terms of the update though SGYP reiterated the launch timing for Trulance, which it expects later this month (March). We continue to believe Trulance will see strong uptake among patients and physicians given its improved tolerability and dosing profile relative to incumbent brands and benefit from the overall category growth of the chronic constipation market. We remain positive on SGYP's hybrid commercialization strategy which incorporates company-hired managers and reps from a contract sales organization. With the financing overhang gone, we believe shares are poised to appreciate as we begin to see paid scripts ramp which could be several months into the launch. Reiterate Outperform." (3/2/2017)

Synergy Pharmaceuticals saw a increase in short interest in the month of July. As of July 14th, there was short interest totalling 60,743,279 shares, an increase of 1.6% from the June 30th total of 61,710,506 shares. Based on an average trading volume of 2,725,840 shares, the days-to-cover ratio is presently 22.3 days. Approximately 27.1% of the company's stock are sold short.

Some companies that are related to Synergy Pharmaceuticals include Halozyme Therapeutics (HALO), Radius Health (RDUS), Lexicon Pharmaceuticals (LXRX), NovoCure Limited (NVCR), Array BioPharma (ARRY), Acceleron Pharma (XLRN), Dermira (DERM), Clinigen Group PLC (CLIN), Xencor (XNCR), Amarin Corporation PLC (AMRN), Insmed (INSM), Acorda Therapeutics (ACOR), Forward Pharma A/S (FWP), NeuroDerm (NDRM), Omeros Corporation (OMER), Aduro Biotech (ADRO), Ascendis Pharma A/S (ASND) and PTC Therapeutics (PTCT).

Synergy Pharmaceuticals' management team includes the folowing people:

• Gary S. Jacob Ph.D., Chairman of the Board, President, Chief Executive Officer
• Gary G. Gemignani, Chief Financial Officer, Executive Vice President
• Marino Garcia, Executive Vice President, Chief Strategy Officer
• Patrick H. Griffin M.D., Executive Vice President, Chief Medical Officer
• Troy Hamilton, Executive Vice President, Chief Commercial Officer
• Bernard F. Denoyer CPA, Senior Vice President, Finance, Secretary
• Melvin K. Spigelman M.D., Lead Independent Director
• Thomas H. Adams Jr. Ph.D., Independent Director
• John P. Brancaccio CPA, Independent Director
• Timothy S. Callahan, Independent Director

Synergy Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Trellus Management Company LLC (0.15%), Clear Harbor Asset Management LLC (0.13%), Nisa Investment Advisors LLC (0.13%), Cheyne Capital Management UK LLP (0.06%), Carl Domino Inc (0.04%) and America First Investment Advisors LLC (0.03%). Company insiders that own Synergy Pharmaceuticals stock include Alan Joslyn, Bernard Denoyer, Gary S Jacob, John P Brancaccio and Paulson & Co Inc. View Institutional Ownership Trends for Synergy Pharmaceuticals.

Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including State Treasurer State of Michigan. Company insiders that have sold Synergy Pharmaceuticals stock in the last year include John P Brancaccio and Paulson & Co Inc. View Insider Buying and Selling for Synergy Pharmaceuticals.

Synergy Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Trellus Management Company LLC, Nisa Investment Advisors LLC, Clear Harbor Asset Management LLC and Janney Montgomery Scott LLC. Company insiders that have bought Synergy Pharmaceuticals stock in the last two years include Gary S Jacob and John P Brancaccio. View Insider Buying and Selling for Synergy Pharmaceuticals.

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $4.19.